Context Therapeutics Inc. financial data

Symbol
CNTX on Nasdaq
Industry
Pharmaceutical Preparations
Location
2001 Market Street, Suite 3915 Unit #15, Philadelphia, PA
State of incorporation
DE
Fiscal year end
December 31
Former names
Context Therapeutics LLC (to 5/3/2021)
Latest financial report
10-Q - Q3 2024 - Nov 6, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.01K % +147%
Debt-to-equity 5.3 % -62.1%
Return On Equity -58.8 % +25.1%
Return On Assets -55.8 % +18.9%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 75M shares +370%
Common Stock, Shares, Outstanding 75M shares +370%
Entity Public Float 23.8M USD -25.2%
Common Stock, Value, Issued 75K USD +370%
Weighted Average Number of Shares Outstanding, Basic 80.5M shares +404%
Weighted Average Number of Shares Outstanding, Diluted 80.5M shares +404%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense 7.06M USD -4.52%
Operating Income (Loss) -32.5M USD -47.8%
Nonoperating Income (Expense) -66.3K USD -1979%
Net Income (Loss) Attributable to Parent -30.2M USD -45.3%
Earnings Per Share, Basic -0.91 USD/shares +30%
Earnings Per Share, Diluted -0.91 USD/shares +30%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 84.8M USD +291%
Assets, Current 86.1M USD +275%
Property, Plant and Equipment, Net 14.9K USD -17.7%
Operating Lease, Right-of-Use Asset 244K USD
Other Assets, Noncurrent 0 USD -100%
Assets 86.3M USD +276%
Accounts Payable, Current 1.03M USD -43.7%
Employee-related Liabilities, Current 627K USD -0.86%
Accrued Liabilities, Current 1.2M USD -56.8%
Liabilities, Current 2.33M USD -49.3%
Operating Lease, Liability, Noncurrent 140K USD
Liabilities 2.47M USD -46.3%
Retained Earnings (Accumulated Deficit) -91.4M USD -49.2%
Stockholders' Equity Attributable to Parent 83.9M USD +356%
Liabilities and Equity 86.3M USD +276%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.36M USD +23.9%
Net Cash Provided by (Used in) Financing Activities 0 USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 200M shares +100%
Common Stock, Shares, Issued 75M shares +370%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -4.36M USD +23.9%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 84.8M USD +291%
Deferred Tax Assets, Valuation Allowance 16.6M USD +80.7%
Deferred Tax Assets, Gross 16.8M USD +77.9%
Operating Lease, Liability 200K USD
Payments to Acquire Property, Plant, and Equipment 0 USD -100%
Operating Lease, Liability, Current 104K USD
Operating Lease, Weighted Average Discount Rate, Percent 0.05 pure 0%
Deferred Tax Assets, Operating Loss Carryforwards 7.75M USD +32.1%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Additional Paid in Capital 175M USD +120%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 2.57K USD -19.6%
Share-based Payment Arrangement, Expense 866K USD -18.6%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%